Clinical trials: IPF
Pulmonary Fibrosis
Supplemental Oxygen in Pulmonary Fibrosis
To enhance understanding of supplemental oxygen-its utility in and adoption by patients with pulmonary fibrosis-by examining how patients perceive it and by determining how perceptions and patient-centered outcome measures change…
- Trial name
- NCT01961362
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Lung Disease
Immunological Characterization of Bronchoalveolar Cells in Normals
To obtain the monocytes (white blood cells) from normal volunteers for the purpose of studying how proteins, fats, carbohydrates, as well as RNA and DNA for gene expression, relate to immunity.
- Trial name
- NCT00843414
- Where
- United States
- Volunteers
- 1,232 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Idiopathic Pulmonary Fibrosis
Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
This is a randomized, open-label, 2-treatment, 2-period, crossover steady state study conducted to evaluate the comparative bioavailability/bioequivalence of pirfenidone after multi-dose administration of EXCL-100 at doses of…
- Trial name
- NCT05428150
- Testing
- Esbriet 267 MG Oral Capsule, EXCL-100, 600 MG Oral Tablet
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Excalibur Pharmaceuticals, Inc.
Pulmonary Fibrosis, Interstitial Lung Disease
Pulmonary Fibrosis Foundation Community Registry
Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members.
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT05382572
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Pulmonary Fibrosis Foundation
Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF)
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327
The purpose of this study is to assess the safety, tolerability, kinetics and test-retest repeatability of the novel LPA1 positron emission tomography (PET) ligand 18F-BMS-986327 in healthy participants and participants with…
- Trial name
- NCT04069143
- Testing
- 18F-BMS-986327
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis
129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study
This research is a study to test the reliability of Hyperpolarized Xenon MRI (HXe MRI) as a biomarker in interstitial lung disease.
- Trial name
- NCT04677426
- Testing
- Hyperpolarized Xe129
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS
- Trial name
- NCT06683612
- Testing
- PIPE-791
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis
A Trial of HRS-9813 in Healthy Subjects
The study is being conducted to evaluate the safety and pharmacokinetics of HRS-9813 after multiple oral administration in healthy subjects.
- Trial name
- NCT06821464
- Testing
- HRS-9813
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Pulmonary Healthy Controls, Interstitial Lung Disease
Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
Current diagnostic tools used in interstitial lung disease (ILD) do not meet the challenges set by the complex pathophysiology of this heterogenous group.
- Conditions
- Pulmonary Healthy Controls, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Non-specific Interstitial Pneumonia
- Trial name
- NCT02827734
- Testing
- multiple breath washout tests, impulse oscillometry, body plethysmography
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universitätsmedizin Mannheim
Healthy, Pulmonary Fibrosis
Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis
Pulmonary fibrosis (PF) is a condition in which the lungs of a patient become scarred and fibrous. It has been known to occur in as many as 40% of patients diagnosed with rheumatoid arthritis (RA).
- Conditions
- Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
- Trial name
- NCT00001885
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Idiopathic Pulmonary Fibrosis, Cardiac Fibrosis
Cardiovascular Fibrosis in Idiopathic Pulmonary Fibrosis
Fibroproliferative diseases, including pulmonary, cardiac and vascular fibrosis share common pathogenetic mechanisms. Furthermore, cardiovascular comorbidities are frequently found in patients with IPF.
- Conditions
- Idiopathic Pulmonary Fibrosis, Cardiac Fibrosis, Arterial Fibrosis
- Trial name
- CardioIPF (NCT04177251)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- San Gerardo Hospital
Pulmonary Fibrosis of Any Cause, Primary Supporters/Caretakers of Patients With Pulmonary Fibrosis
Pulmonary Fibrosis Contact Registry
As the name states, contact registries securely store contact information from groups of reasonably well-characterized patients (or primary supporters/caregivers) who are interested in being informed about ongoing or future…
- Trial name
- NCT01935726
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Idiopathic Pulmonary Fibrosis
To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers
An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between DWN12088 and Pirfenidone or Nintedanib in healthy volunteers
- Trial name
- NCT04888715
- Testing
- DWN12088, Pirfenidone, Nintedanib
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Idiopathic Pulmonary Fibrosis(IPF), Solid Tumor
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults
The Primary objectives of this study are to evaluate the safety and tolerability of ZSP1603 and the Secondary objective is to estimate the pharmacokinetic (PK) parameters after orally administered once daily of ZSP1603.
- Trial name
- NCT03619616
- Testing
- ZSP1603 7.5 mg, ZSP1603 12.5 mg, ZSP1603 25 mg
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Idiopathic Pulmonary Fibrosis
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
This is a randomized, double-blind, placebo-controlled Phase 1 study of SAD (Part 1) and MAD (Part 2) of orally administered GNS-3545 in healthy adult subjects. The food effect will be assessed in one cohort in Part 1.
- Trial name
- NCT07225296
- Testing
- GNS-3545
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Genosco Inc.
Familial Pulmonary Fibrosis
GEN-FPF: Genetic Exploration of Familial Pulmonary Fibrosis
Pulmonary fibrosis (PF) is a progressive lung disease marked by tissue scarring and impaired breathing. Familial pulmonary fibrosis (FPF) makes up 10-20% of PF cases and shares features with idiopathic PF (IPF), but the genetic…
- Trial name
- GEN-FPF (NCT07251725)
- Where
- Italy
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Idiopathic Pulmonary Fibrosis (IPF)
A Phase I Study of HW241045 in Healthy Subjects
This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW241045 in healthy participants.
- Trial name
- NCT07593690
- Testing
- HW241045 Formulation A, HW241045 Formulation B
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Interstitial Pulmonary Fibrosis, Emphysema
Lung Diffusing Capacities Normality Thresholds in Pulmonary Fibrosis and Emphysema
The investigators tested the usefulness of lung diffusing capacities for carbon monoxide (DLco) and nitric oxide (DLNO) normality thresholds of 5th and 2.5th percentiles for the assessment of intersitial pulmonary fibrosis (IPF)…
- Trial name
- DLNO-DLCO_emph (NCT07091838)
- Where
- Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
IPF
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects
The purpose of this study is to investigate the safety, PK, and immunogenicity of a single intravenous administration of HLX6018 in healthy subjects, based on the preliminary efficacy and safety established through in vitro and…
- Trial name
- NCT06310746
- Testing
- GARP/TGF-β1 monoclonal antibody
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Idiopathic Pulmonary Fibrosis
A Validation and Dosimetry Study of GSK2634673F PET Ligand
This is a methodology study to examine the quantification of GSK2634673F binding in humans, with the aim of characterising a robust, non-invasive method to quantify the specific binding signal for the alpha(V)beta6 protein in…
- Trial name
- NCT02052297
- Testing
- GSK2634673F
- Where
- 2 sites in United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline